Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Astellas Pharma ( (JP:4503) ) has issued an update.
Astellas Pharma has revised its financial forecasts for FY2025, projecting higher revenues and profits due to the strong performance of its strategic brands, including VYLOY™ for gastric cancer, PADCEV™ for urothelial cancer, and XTANDI™ for prostate cancer. The company’s cost management initiative, Sustainable Margin Transformation, is also expected to positively impact its financial performance, highlighting Astellas’ robust market positioning and strategic growth in the life sciences sector.
The most recent analyst rating on (JP:4503) stock is a Buy with a Yen1805.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.
More about Astellas Pharma
Astellas is a global life sciences company dedicated to transforming innovative science into value for patients. It offers transformative therapies in various disease areas, including oncology, ophthalmology, urology, immunology, and women’s health. The company is at the forefront of developing new healthcare solutions for diseases with high unmet medical needs.
Average Trading Volume: 6,731,854
Technical Sentiment Signal: Buy
Current Market Cap: Yen2837.1B
See more insights into 4503 stock on TipRanks’ Stock Analysis page.